Combination Therapy for Advanced Cancer

The combination strategy was developed according to previous treatment, individual characteristics, patient willingness, and economic considerations. All patients received at least one cycle of combination therapy with antiangiogenic agents and PD-1 inhibitors. The antiangiogenic agents are apatinib and anlotinib, and the PD‐1 inhibitors are camrelizumab and sintilimab. Anlotinib (12 mg/day or 10 mg/day) was taken orally from day one to 14 every 21 days and apatinib (500 mg/day or 250 mg/day) was taken orally daily. Simultaneously, patients were intravenously administered with sintilimab 200 mg or camrelizumab 200 mg every three weeks, The combination therapy was repeated every three weeks until PD, intolerance to toxicity, or refusal of treatment by patients or physicians. Patients experienced dose delay, dose reduction, treatment interruption, and discontinuation of antiangiogenic drugs based on the grade of toxicity. However, the dose of PD-1 inhibitors was not allowed to be adjusted. If one of two regimens could not be tolerated, the other could be continued.